Literature DB >> 28829205

Potential applications of Bruton's tyrosine kinase inhibitors for the prevention of allergic reactions.

Melanie C Dispenza1, Jennifer A Regan1, Bruce S Bochner1.   

Abstract

Entities:  

Keywords:  Anaphylaxis; Bruton’s tyrosine kinase (BTK); basophils; desensitization; hypersensitivity; ibrutinib; immunotherapy; mast cells

Mesh：

Substances：

Year:  2017        PMID： 28829205      PMCID： PMC5890333          DOI： 10.1080/1744666X.2017.1370374

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN： 1744-666X            Impact factor:   4.473


× No keyword cloud information.
  17 in total

1.  Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor.

Authors:  Donald MacGlashan; Lee A Honigberg; Ashley Smith; Joseph Buggy; John T Schroeder
Journal:  Int Immunopharmacol       Date:  2011-01-14       Impact factor: 4.932

2.  A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy.

Authors:  Satya D Narisety; Pamela A Frischmeyer-Guerrerio; Corinne A Keet; Mark Gorelik; John Schroeder; Robert G Hamilton; Robert A Wood
Journal:  J Allergy Clin Immunol       Date:  2014-12-18       Impact factor: 10.793

Review 3.  Combining anti-IgE with oral immunotherapy.

Authors:  Chunrong Lin; Ivan T Lee; Vanitha Sampath; Chitra Dinakar; Rosemarie H DeKruyff; Lynda C Schneider; Kari Christine Nadeau
Journal:  Pediatr Allergy Immunol       Date:  2017-09-07       Impact factor: 6.377

4.  Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity.

Authors:  Jennifer A Regan; Yun Cao; Melanie C Dispenza; Shuo Ma; Leo I Gordon; Adam M Petrich; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2017-04-04       Impact factor: 10.793

5.  Suppression of the immunologic response to peanut during immunotherapy is often transient.

Authors:  Mark Gorelik; Satya D Narisety; Anthony L Guerrerio; Kristin L Chichester; Corinne A Keet; Anja P Bieneman; Robert G Hamilton; Robert A Wood; John T Schroeder; Pamela A Frischmeyer-Guerrerio
Journal:  J Allergy Clin Immunol       Date:  2014-12-24       Impact factor: 10.793

6.  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Authors:  Ranjana H Advani; Joseph J Buggy; Jeff P Sharman; Sonali M Smith; Thomas E Boyd; Barbara Grant; Kathryn S Kolibaba; Richard R Furman; Sara Rodriguez; Betty Y Chang; Juthamas Sukbuntherng; Raquel Izumi; Ahmed Hamdy; Eric Hedrick; Nathan H Fowler
Journal:  J Clin Oncol       Date:  2012-10-08       Impact factor: 44.544

7.  Food allergy: a practice parameter update-2014.

Authors:  Hugh A Sampson; Seema Aceves; S Allan Bock; John James; Stacie Jones; David Lang; Kari Nadeau; Anna Nowak-Wegrzyn; John Oppenheimer; Tamara T Perry; Christopher Randolph; Scott H Sicherer; Ronald A Simon; Brian P Vickery; Robert Wood; David Bernstein; Joann Blessing-Moore; David Khan; David Lang; Richard Nicklas; John Oppenheimer; Jay Portnoy; Christopher Randolph; Diane Schuller; Sheldon Spector; Stephen A Tilles; Dana Wallace; Hugh A Sampson; Seema Aceves; S Allan Bock; John James; Stacie Jones; David Lang; Kari Nadeau; Anna Nowak-Wegrzyn; John Oppenheimer; Tamara T Perry; Christopher Randolph; Scott H Sicherer; Ronald A Simon; Brian P Vickery; Robert Wood
Journal:  J Allergy Clin Immunol       Date:  2014-08-28       Impact factor: 10.793

8.  The phosphoinositide 3-kinase-dependent activation of Btk is required for optimal eicosanoid production and generation of reactive oxygen species in antigen-stimulated mast cells.

Authors:  Hye Sun Kuehn; Emily J Swindle; Mi-Sun Kim; Michael A Beaven; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

9.  Involvement of Bruton's tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production.

Authors:  D Hata; Y Kawakami; N Inagaki; C S Lantz; T Kitamura; W N Khan; M Maeda-Yamamoto; T Miura; W Han; S E Hartman; L Yao; H Nagai; A E Goldfeld; F W Alt; S J Galli; O N Witte; T Kawakami
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

10.  Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia.

Authors:  Julio C Chavez; Eva Sahakian; Javier Pinilla-Ibarz
Journal:  Core Evid       Date:  2013-05-16
View more
  7 in total

1.  Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy.

Authors:  Melanie C Dispenza; Jacqueline A Pongracic; Anne M Singh; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2018-01-31       Impact factor: 10.793

Review 2.  The role of basophils as innate immune regulatory cells in allergy and immunotherapy.

Authors:  Salvatore Chirumbolo; Geir Bjørklund; Andrea Sboarina; Antonio Vella
Journal:  Hum Vaccin Immunother       Date:  2018-01-18       Impact factor: 3.452

3.  Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis.

Authors:  Melanie C Dispenza; Rebecca A Krier-Burris; Krishan D Chhiba; Bradley J Undem; Piper A Robida; Bruce S Bochner
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

Review 4.  Effects of BTK signalling in pathogenic microorganism infections.

Authors:  Bingjue Ye; Cheng Zhou; Huiting Guo; Min Zheng
Journal:  J Cell Mol Med       Date:  2019-08-08       Impact factor: 5.310

Review 5.  The Use of Bruton's Tyrosine Kinase Inhibitors to Treat Allergic Disorders.

Authors:  Melanie C Dispenza
Journal:  Curr Treat Options Allergy       Date:  2021-04-16

6.  Inhibition of Bruton's Tyrosine Kinase Protects Against Burn Sepsis-Induced Intestinal Injury.

Authors:  Jia Wan; Xi Yu; Jia-Qi Niu; Le Qiu; Fei Wang; Xu-Lin Chen
Journal:  Front Med (Lausanne)       Date:  2022-02-24

7.  Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers.

Authors:  Tobias Litzenburger; Jürgen Steffgen; Ewald Benediktus; Fabian Müller; Armin Schultz; Elliott Klein; Meera Ramanujam; Christian Harcken; Alpana Gupta; Jing Wu; Sabrina Wiebe; Xiujiang Li; Mary Flack; Steven J Padula; Sudha Visvanathan; Andreas Hünnemeyer; Jianan Hui
Journal:  Br J Clin Pharmacol       Date:  2020-11-20       Impact factor: 3.716
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.